Navigation

Appraisals in development

This table lists NICE technology appraisals. The list can be sorted by title (alphabetically), wave number, anticipated publication date and process. You can also click the appraisal title for full details, or click a column heading to sort the list by that column.

Appraisals in development

Title Anticipated publication date Referral date Process
Acute coronary syndrome - prasugrel with PCI (review TA182) [ID 648] Aug 2014 MTA
Acute coronary syndrome - rivaroxaban [ID532] Mar 2015 May 2012 STA
Alcohol dependence - nalmefene [ID660] Nov 2014 Oct 2013 STA
Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin) (inc rev TA142) [ID541] Aug 2014 MTA
Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) - adalimumab, etanercept infliximab and golimumab (inc rev TA143 and TA233) Jan 2015 MTA
Arrythmias - ICDs & Heart failure - cardiac resynchronisation [ID481] Jun 2014 MTA
Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95] TBC Jul 2009 STA
Atrial fibrillation - idraparinux sodium [ID375] TBC Nov 2005 STA
Atrial fibrillation - vernakalant [ID454] TBC May 2011 STA
Atrial fibrillation - ximelagatran [ID376] TBC Oct 2000 MTA
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83] TBC Apr 2009 STA
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405] TBC Nov 2011 STA
Bradycardia - dual chamber pacemakers (review of TA88) [ID697] Feb 2015 MTA
Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319] TBC Mar 2009 STA
Breast cancer (advanced or metastatic) - lapatinib [ID20] TBC Dec 2006 STA
Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115] TBC Dec 2007 STA
Breast cancer (early) - intrabeam radiotherapy system [ID618] Nov 2014 MTA
Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517] TBC Nov 2011 STA
Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58] TBC Mar 2009 STA
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488] TBC Nov 2011 STA
Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel) [ID523] TBC Jul 2012 STA
Breast cancer (HER2 positive, unresectable) - trastuzumab emtansine (after trastuzumab & taxane) [ID603] Aug 2014 STA
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377] TBC Dec 2007 STA
Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345] Oct 2011 MTA
Breast cancer - intensity modulated radiotherapy [ID16] TBC Mar 2008 MTA
Cardiac transplantation (rejection) - everolimus [ID114] TBC Jul 2009 STA
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350] TBC Jul 2010 MTA
Clinically isolated syndrome - beta interferons and glatiramer acetate [ID109] TBC Jul 2009 MTA
Clostridium difficile associated diarrhoea - tolevamer [ID378] TBC Jun 2007 STA
Colon cancer (adjuvant) - irinotecan [ID379] TBC Jun 2004 STA
Colorectal cancer (metastatic) - regorafenib [ID593] TBC STA
Constipation (chronic idiopathic) - lubiprostone [ID725] Oct 2014 STA
Constipation (opioid induced) - lubiprostone [ID646] Oct 2014 STA
Constipation (opioid-induced) - naloxegol [ID674] Jul 2015 Feb 2014 STA
Crohn's disease (moderate to severe) - vedolizumab [ID690] Jun 2015 Jan 2014 STA
Deep vein thrombosis, pulmonary embolism - dabigatran etexilate (treatment, prevention) [ID483] Oct 2014 STA
Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380] TBC Mar 2003 MTA
Diabetes (type 2) - canagliflozin [ID554] Jun 2014 STA
Diabetes (type 2) - empagliflozin [ID641] Dec 2014 Oct 2013 STA
Diabetes - buccal insulin [ID311] TBC Feb 2010 STA
Diabetic foot ulcers - new treatments [ID381] TBC Mar 2003 MTA
Diabetic retinopathy - ruboxistaurin [ID382] TBC Nov 2005 STA
Dupuytren's contracture - collagenase clostridium histolyticum [ID621] Jan 2015 MTA
Falls - faller's clinics [ID103] TBC Oct 2000 MTA
Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) TBC STA
Gastrointestinal stromal tumours - imatinib (adjuvant) (rev TA196) [ID696] Oct 2014 STA
Generalised anxiety disorder - quetiapine [ID347] TBC Jun 2010 STA
Glaucoma - lerdelimumab (CAT-152) [ID383] TBC Jun 2004 STA
Glioblastoma - bevacizumab [ID80] TBC Nov 2008 STA
Head and neck cancer - contusugene ladenovec [ID76] TBC Mar 2009 STA
Head and neck cancer - intensity modulated radiotherapy [ID15] TBC Mar 2008 MTA
Heart failure (acute decompensated) - nesiritide [ID384] TBC Oct 2000 STA
Heart failure (acute) - serelaxin [ID673] TBC Dec 2013 STA
Hepatic encephalopathy - rifaximin (maintenance) [ID496] TBC Nov 2011 STA
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111] TBC MTA
Hepatitis C (chronic) - simeprevir [ID668] Jan 2015 Dec 2013 STA
Hepatitis C (chronic) - sofosbuvir [ID654] Oct 2014 Oct 2013 STA
Hepatitis C (genotype 1, chronic) - faldaprevir [ID670] Feb 2015 Feb 2014 STA
Hypercholesterolemia - mipomersen [ID524] TBC May 2012 STA
Juvenile idiopathic arthritis - abatacept [ID27] TBC Jun 2008 STA
Juvenile idiopathic arthritis - adalimumab [ID385] TBC Jun 2008 STA
Kidney disease (autosomnal dominant polycystic) - tolvaptan [ID652] TBC Oct 2013 STA
Kidney transplantation (rejection) - belatacept [ID87] TBC Jul 2009 STA
Kidney transplantation (rejection) - everolimus [ID117] TBC Jul 2009
Knee cartilage defects - autologous chondrocyte implantation [ID686] Jul 2015 Oct 2013 MTA
Leukaemia (acute lymphoblastic) - dasatinib [ID386] TBC Jun 2008 STA
Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650] Feb 2015 Dec 2013 STA
Leukaemia (chronic lymphocytic, previously untreated) - ofatumumab [ID642] Apr 2015 Oct 2013 STA
Leukaemia (chronic myeloid) - nilotinib (discontinued) [ID79] May 2011 Mar 2009 STA
Lung cancer (non-small cell) - afatinib [ID357] TBC Jul 2010 STA
Lung cancer (non-small cell) - erlotinib & gefitinib (post chemotherapy) (rev TA162, TA175) [ID620] Jun 2014 MTA
Lung cancer (non-small cell) - nintedanib [ID438] Apr 2015 Dec 2013 STA
Lung cancer (non-small-cell) - cetuximab [ID9] TBC Dec 2007 STA
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44] TBC Nov 2008 STA
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43] TBC Nov 2008 STA
Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46] TBC Nov 2008 STA
Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407] TBC Nov 2010 STA
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609] TBC May 2012 STA
Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434] TBC Jan 2011 STA
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368] TBC Sep 2010 STA
Macular oedema (diabetic) - dexamethasone intravitreal implant [ID653] Apr 2015 Feb 2014 STA
Macular oedema (diabetic) - pegaptanib sodium [ID452] TBC Mar 2011 STA
Major depressive disorder - vortioxetine [ID583] May 2015 STA
Melanoma (advanced and metastatic) - temozolomide [ID316] TBC Jun 2008 STA
Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib [ID605] TBC STA
Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib [ID605] TBC STA
Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570] May 2015 Oct 2013 STA
Melanoma (previously untreated unresectable stage III or IV) - ipilimumab [ID74] TBC Nov 2008 STA
Multiple myeloma (newly diagnosed) - lenalidomide [ID474] TBC Jul 2011 STA
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501] TBC Nov 2011 STA
Multiple myeloma (relapsed, refractory) - pomalidomide [ID666] Feb 2015 Dec 2013 STA
Multiple myeloma - bortezomib (consolidation therapy) [ID529] TBC May 2012 STA
Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) [ID475] TBC Jul 2011 STA
Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171) [ID667] Jul 2014 STA
Multiple sclerosis (primary-progressive) - fingolimod [ID62] TBC Nov 2008 STA
Multiple sclerosis (relapsing-remitting) - alemtuzumab [ID539] May 2014 STA
Multiple sclerosis (relapsing-remitting) - dimethyl fumarate [ID585] TBC STA
Multiple sclerosis (relapsing-remitting) - laquinimod [ID560] Oct 2014 STA
Multiple sclerosis - cladribine [ID64] TBC Nov 2008 STA
Multiple sclerosis - sativex [ID387] TBC May 2002 MTA
Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480] TBC Jul 2011 STA
Obesity - lorcaserin [ID337] TBC Jun 2010 STA
Obesity - phentermine (with topiramate) [ID543] TBC Jul 2012 STA
Organ rejection (liver transplantation, prevention) - everolimus [ID559] Jul 2014 STA
Osteoarthritis - diacerein [ID332] TBC Mar 2010 MTA
Osteoarthritis - naproxcinod [ID417] TBC Nov 2010 STA
Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388] TBC MTA
Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545] TBC Oct 2013 STA
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468] TBC MTA
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564] TBC STA
Pancreatic adenocarcinoma (untreated, metastatic) - paclitaxel albumin-bound nanoparticles (with gemcitabine) [ID680] Jan 2015 Dec 2013 STA
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566] TBC STA
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513] Aug 2015 STA
Pancreatic cancer - capectitabine [ID389] TBC Dec 2007 STA
Primary (heterozygous-familial and non-familial) hypercholesterolaemia - ezetimibe (review of TA132) [ID627] Jan 2016 MTA
Prostate cancer (advanced, hormone dependent) - degarelix depot [ID590] May 2014 STA
Prostate cancer (hormone refractory) - atrasentan [ID390] TBC Jun 2004 STA
Prostate cancer (hormone relapsed, bone metastases) - radium-223 dichloride [ID576] TBC STA
Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel) [ID600] Jun 2014 STA
Prostate cancer (metastatic, hormone relapsed) - sipuleucel-T (1st line) [ID573] Feb 2015 STA
Prostate cancer (metastatic, hormone relapsed, not treated with chemotherapy) - abiraterone acetate (with prednisolone) [ID503] TBC Nov 2011 STA
Prostate cancer (metastatic, hormone-relapsed) - enzalutamide [ID683] May 2015 Feb 2014 STA
Prostate cancer (prevention) - dutasteride [ID75] TBC Mar 2009 STA
Prostate cancer - intensity modulated radiotherapy [ID17] TBC Mar 2008 MTA
Psoriasis (plaque, moderate to severe) - secukinumab [ID718] Jul 2015 Feb 2014 STA
Psoriasis - briakinumab (suspended) [ID65] TBC Nov 2008 STA
Psoriatic arthritis (active) - ustekinumab [ID607] May 2014 STA
Psoriatic arthritis (moderate to severe) - leflunomide [ID391] TBC Nov 2005 STA
Pulmonary arterial hypertension (adults) - drugs [ID12] TBC Apr 2005 MTA
Renal cell carcinoma (advanced) - axitinib [ID518] Jun 2014 Feb 2012 STA
Renal cell carcinoma (second line metastatic) - pazopanib [ID70] Jan 2011 Nov 2008 STA
Renal transplantation (adults) - immunosuppressive therapy (including Review of TA 85) [ID456] Sep 2014 MTA
Renal transplantation (children, adolescents) - immunosuppressive regimens (review of TA99) [ID346] TBC MTA
Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333] TBC Apr 2010 STA
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18] TBC Jun 2004 MTA
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review [ID537] TBC MTA
Rheumatoid arthritis - tofacitinib [ID526] TBC May 2012 STA
Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415] TBC Sep 2011 STA
Systemic lupus erythematosus (autoantibody-positive) - belimumab [ID416] TBC Nov 2010 STA
Systemic lupus erythematosus - prasterone [ID392] TBC Oct 2000 MTA
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504] TBC Nov 2011 STA
Thrombophilia [ID393] TBC Oct 2000 MTA
Ulcerative colitis (moderate to severely active) - vedolizumab [ID691] Jun 2015 Dec 2013 STA
Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695] Jan 2015 MTA
Venous leg ulcers - new treatments [ID394] TBC Jun 2003 MTA
Venous thromboembolism (prevention) - rivaroxaban [ID463] TBC May 2011 STA
Venous thromboembolism (recurrent) - idraparinux sodium [ID395] TBC Nov 2005 STA
Venous thromboembolism (VTE) - ximelagatran [ID396] TBC Oct 2000 MTA
Venous thromboembolism - apixaban (acute medical illness) [ID310] TBC Jan 2010 STA

This page was last updated: 22 April 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.